The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is based on the Phase 3 BRUIN CLL-313 trial, which showed Jaypirca significantly delays disease progression compared to chemoimmunotherapy, with a favorable safety profile. Jaypirca is the first non-covalent BTK inhibitor approved for this use, offering a new targeted therapy option for patients. Lilly continues to study Jaypirca in multiple ongoing Phase 3 trials to further define its role in CLL/SLL treatment.
Following the FDA's expanded approval of Lilly's Jaypirca for certain leukemia patients, Eli Lilly And Co shares are trading slightly lower on Pluang. As of Oct 03, 2026 02:21 WIB, LLY is priced at USD 1,145.85, down 0.48% for the day. The stock holds a market cap of $1.02 trillion and a dividend yield of 0.6%, with typical investor hold time around 93 days.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
